The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
Applications include detailed scientific rationale and supporting clinical evidence
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
The partnership also sets the stage for broader collaboration on rare disease treatments
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Subscribe To Our Newsletter & Stay Updated
